Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

46.84 -3.44 (-6.84%)
Streaming Delayed Price Updated: 2:04 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over upcoming COVID and RSV sales. 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
Smart Money Is Betting Big In MRNA Options
Via Benzinga
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Both stocks have made significant breakthroughs. 
Via The Motley Fool
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Via ACCESSWIRE
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda. 
Via Benzinga
Topics Government
Exposures Political
Moderna (MRNA) Q3 2024 Earnings Call Transcript
MRNA earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Via ACCESSWIRE
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
In-Depth Examination Of 15 Analyst Recommendations For Moderna
Via Benzinga
Moderna Q3 Revenue Beats On Updated COVID-19 Vaccine, Slashes Expenses For 2024
Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations. 
Via Benzinga
Exposures COVID-19
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?
The company reported just $10 million in sales of its RSV vaccine, mResvia, widely missing expectations. 
Via Investor's Business Daily
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped
On Wednesday, Ark Invest, led by Cathie Wood, made significant trades in Moderna Inc. (NASDAQ:MRNA) and Square Inc. (NYSE:SQ). The Moderna Trade 
Via Benzinga
Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.
Robert Kennedy Jr. revealed Trump's directive to tackle health agency corruption, promote science, and end chronic disease. 
Via Benzinga
Topics Government
Exposures Political
Moderna to Present at Upcoming Conferences in November 2024
Via ACCESSWIRE
Behind the Scenes of Moderna's Latest Options Trends
Via Benzinga
Moderna Unusual Options Activity For October 22
Via Benzinga
A Closer Look at Moderna's Options Market Dynamics
Via Benzinga
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over
Perhaps this list is a good place to start bargain-hunting. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night. 
Via The Motley Fool
These 10 Stocks Were S&P 500's Top Performers In Biden's First Year: Could The Trend Continue If Harris Wins 2024 Election?
A look at the top 10 performing S&P 500 stocks in 2021 could point to trends to watch if Kamala Harris wins the 2024 election. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Moderna Stock Trading Higher On Monday?
Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. 
Via Benzinga
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Large-Cap Stocks In Trouble - Sunday, Oct. 27
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Moderna Named a Top Employer by Science for Tenth Consecutive Year
Via ACCESSWIRE
How Bad Is This News for Novavax?
Novavax stock fell 20% in one trading session on the news. 
Via The Motley Fool
Large-Cap Stocks In Trouble - Saturday, Oct. 19
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Benzinga Bulls And Bears: Apple, Tesla, Netflix, Oklo — And Dogecoin, Meme Coins Outpace Corporate Giants
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.